A novel formulation for dolutegravir has been developed to improve HIV treatment options for children. Dr Kimberly Smith from ViiV Healthcare discusses the benefits of this new dispersible tablet.
List view / Grid view
Filter the results
Phase 3 trials of Gilead’s fixed-dose (BIC/FTC/TAF) combination for HIV show high tolerability and low resistance